Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr 21;18(10):pyv042.
doi: 10.1093/ijnp/pyv042.

Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank

Elizabeth Scarr  1 , Mark J Millan  2 , Sabine Bahn  2 , Alessandro Bertolino  2 , Christoph W Turck  2 , Shitij Kapur  2 , Hans-Jürgen Möller  2 , Brian Dean  2
Affiliations
Review

Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank

Elizabeth Scarr et al. Int J Neuropsychopharmacol. .

Abstract

Background: A think tank sponsored by the Collegium Internationale Neuropsychopharmacologium (CINP) debated the status and prospects of biological markers for psychiatric disorders, focusing on schizophrenia and major depressive disorder.

Methods: Discussions covered markers defining and predicting specific disorders or domains of dysfunction, as well as predicting and monitoring medication efficacy. Deliberations included clinically useful and viable biomarkers, why suitable markers are not available, and the need for tightly-controlled sample collection.

Results: Different types of biomarkers, appropriate sensitivity, specificity, and broad-based exploitability were discussed. Whilst a number of candidates are in the discovery phases, all will require replication in larger, real-life cohorts. Clinical cost-effectiveness also needs to be established.

Conclusions: Since a single measure is unlikely to suffice, multi-modal strategies look more promising, although they bring greater technical and implementation complexities. Identifying reproducible, robust biomarkers will probably require pre-competitive consortia to provide the resources needed to identify, validate, and develop the relevant clinical tests.

Keywords: Animal studies; biomarkers; clinical samples; imaging; psychiatric disorders.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Potential clinical uses for biomarkers in psychiatry.
See this image and copyright information in PMC

References

    1. Andreou C, Bozikas VP. (2013) The predictive significance of neurocognitive factors for functional outcome in bipolar disorder. Curr Opin Psychiatry 26:54–59. - PubMed
    1. Arnedo J, Svrakic DM, Del VC, Romero-Zaliz R, Hernandez-Cuervo H, Fanous AH, Pato MT, Pato CN, de Erausquin GA, Cloninger CR, Zwir I. (2015) Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies. Am J Psych 172:139–153. - PubMed
    1. Barry MJ. (2001) Prostate-specific antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373–1377. - PubMed
    1. Bauer IE, Pascoe MC, Wollenhaupt-Aguiar B, Kapczinski F, Soares JC. (2014) Inflammatory mediators of cognitive impairment in bipolar disorder. J Psychiatr Res 56:18–27. - PMC - PubMed
    1. Belzeaux R, Formisano-Tréziny C, Loundou A, Boyer L, Gabert J, Samuelian JC, Féron F, Naudin J, Ibrahim EC. (2010) Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res 44:1205–1213. - PubMed

Publication types